Pharmacy Times
OCTOBER 4, 2024
Nivolumab is the only PD-1 inhibitor to show statistically significant and clinically meaningful benefits in non-small cell lung cancer compared with chemotherapy.
STAT
OCTOBER 4, 2024
You’ve probably heard of Damar Hamlin, who as starting safety for the Buffalo Bills has helped lead his team to a 3-1 record to start the National Football League season. Damar survived a cardiac arrest during a Monday Night Football game in January 2023, with more than 60,000 people watching in person and another 23 million tuned in.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
OCTOBER 4, 2024
The new screening test provides an easier, convenient option for patients seeking to screen themselves for colorectal cancer.
Drug Topics
OCTOBER 4, 2024
Social pressures, physiological changes, mental health challenges, and burnout all complicate diabetes management among adolescents.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
OCTOBER 4, 2024
Experimental vaccines and therapeutics to combat the deadly Marburg virus will begin arriving this weekend in Rwanda, where they will be used in clinical trials expected to begin soon, a U.S. government official confirmed on Friday. There are currently no licensed vaccines or drugs to prevent or treat Marburg, a cousin of the Ebola family of viruses that transmits and causes illness in the same way as Ebola.
Drug Topics
OCTOBER 4, 2024
Researchers aimed to determine whether or not opioids were appropriate for treating adolescents experiencing chronic pain.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
OCTOBER 4, 2024
Cologuard Plus is approved for adults aged 45 years and older who are at average risk for the disease.
Pharmacy Times
OCTOBER 4, 2024
Major biomarkers for cognitive impairment were observed in hospitalized patients with neurological symptoms.
The Checkup by Singlecare
OCTOBER 4, 2024
You open the medicine cabinet to take a dose of fluconazole prescribed to tackle a stubborn yeast infection. Later, as you meet friends for dinner, you wonder whether it’s safe to enjoy a glass of wine. Fluconazole , also sold under the brand name Diflucan , is a commonly used antifungal medication, but generally, it’s not recommended to drink while taking it.
STAT
OCTOBER 4, 2024
Next year’s Medicare Advantage market will be two things at once: remarkably stable broadly, but rife with changes under the surface. Health insurance companies will still offer older adults a lot of plan choices with low, or completely free, premiums. That’s why the federal government expects enrollment in the $500 billion Medicare Advantage program to grow once again in 2025 — a stark contrast from insurers’ cries that modest payment reforms would damage them and se
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
OCTOBER 4, 2024
High cholesterol levels are known risk factors for atherosclerotic cardiovascular disease.
STAT
OCTOBER 4, 2024
As primary care physicians, we see a scene play out almost daily. A patient is sitting in front of us, explaining her symptoms: She could have difficulty breathing, stress at home, fatigue. We know there is nothing more important than being fully present. However, our minds and eyes keep darting to the computer screen and the growing inbox of messages from other patients: “I forgot my Lipitor for a week, should I double up tomorrow?
Drug Topics
OCTOBER 4, 2024
Check out important updates from the FDA for the week of September 30.
NF2 BioSolutions
OCTOBER 4, 2024
Hello everyone, For the last 3 years, I have been a NF2 BioSolutions-funded PhD student working within Manchester alongside Grace Gregory, and it has been such a rewarding and positive experience, not only for my personal development, but for driving forward our understanding of NF2 -related Schwannomatosis ( NF2 SWN) and potential new treatments. Alas, my PhD has finally come to an end, but I’m please to share with you some of the key findings from my work that will hopefully change the ways in
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
OCTOBER 4, 2024
Bristol Myers Squibb (BMS) has been granted approval by the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC).
NF2 BioSolutions
OCTOBER 4, 2024
Hi everyone! What a journey it has been over the last 3 years, being one of the first two NF2 BioSolutions UK and Europe PhD students alongside Adam! I have enjoyed every moment, and I have made the most of all the opportunities to pass my way through the University of Manchester, NF2 research community and the Charity, all of whom have driven this research forward.
Fierce Pharma
OCTOBER 4, 2024
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo. In 2022, Enjaymo became the first and only therapy specifically approved by the FDA for treating patients with the uncommon blood disorder cold agglutinin disease.
STAT
OCTOBER 4, 2024
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Hello, hello. Today we talk about whether the AI overlords will commandeer cancer research (on top of everything else in this world), WuXi is looking to sell some of its operations, ostensibly because of the BIOSECURE Act, and more.
pharmaphorum
OCTOBER 4, 2024
FDA declares an end to tirzepatide shortage, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.
Outsourcing Pharma
OCTOBER 4, 2024
Rebekah's father passed on his passion for science and problem solving to her and much her of childhood was spent doing fun hands-on activities from taking apart household mechanics to building rockets.
STAT
OCTOBER 4, 2024
Exact Sciences won Food and Drug Administration approval on Friday for an improved version of a stool-based screening test for colon cancer that should result in fewer cancer-free patients receiving unnecessary follow-up colonoscopies. The FDA approved the test, Cologuard Plus, for adults 45 and up with an average risk of cancer based on results from a large clinical trial, dubbed Blue-C, which recruited more than 20,000 participants.
Fierce Healthcare
OCTOBER 4, 2024
Lina Khan, chair of the Federal Trade Commission (FTC), would not rule out the possibility of the agency filing an amicus brief to weigh in on Particle Health's antitrust lawsuit against Epic, she | Lina Khan, chair of the FTC, would not rule out the possibility of the agency filing an amicus brief to weigh in on Particle Health's antitrust lawsuit against Epic, she told a Wisconsin reporter Thursday.
STAT
OCTOBER 4, 2024
Georgina Peacock vividly remembers a night when she admitted 20 babies, all struggling to breathe, into the hospital where she was doing her pediatric medical training. The illness that was robbing them of breath? Respiratory syncytial virus, or RSV. Peacock and many others who are responsible for the care of the country’s youngest children have been moving heaven and earth for the past year and a bit, to make experiences like that a thing of the past.
Pharmacy Times
OCTOBER 4, 2024
Trisha Winroth, PharmD, and Ashly McPhillips, PharmD, discuss how the shingles vaccine works to prevent reactivation of the varicella-zoster virus and reduce shingles risk, and how to effectively address patient concerns and misconceptions about the vaccine’s benefits, symptoms, and complications of shingles.
Fierce Pharma
OCTOBER 4, 2024
After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter International—the U.S.’ top supplier of hospital IV fluids—is laying out det | While progress is already being made after Hurricane Helene, which resulted in water “permeating” Baxter’s large IV fluid production plant in North Carolina, the company cautioned that it does not yet have a timeline for when operations will be back online.
Pharmacy Times
OCTOBER 4, 2024
With a scalable, flexible suite of services and an experienced leadership team, InspiroGene enables manufacturers, payers, and providers to navigate the complex CGT commercialization landscape to ensure patients can access the life-changing treatments they need.
STAT
OCTOBER 4, 2024
A pleasant Friday morning to you! Adam Feuerstein, here, reporting from the Pharmalittle campus, temporarily relocated to Cambridge, Mass., as your regular New Jersey host Ed takes the day off. Like the one-and-only Mr. Pharmalot, I enjoy my daily headlines with a hot cup of joe. Have a great weekend. Italian pharma company Recordati said it will buy from Sanofi the global rights to an approved drug to treat cold agglutinin disease , a rare autoimmune disorder, for $825 million, Reuters re
Pharmacy Times
OCTOBER 4, 2024
Panelists discuss how transplant eligibility significantly influences first-line treatment goals and initial therapy selection in multiple myeloma, often leading to more intensive induction regimens aimed at achieving deep remissions.
Fierce Healthcare
OCTOBER 4, 2024
A proposed rule from the Centers for Medicare & Medicaid Services (CMS) released Oct. | CMS is looking to shake up the risk adjustment model and wants the ability to suspend shady brokers from the insurance marketplace, the agency wrote among other updates in a new proposed rule.
Pharmacy Times
OCTOBER 4, 2024
Panelists discuss how various patient characteristics, including age, fitness level, cytogenetic risk, and comorbidities, influence their decision to use more intensive quadruplet regimens like D-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) vs standard triplet regimens, such as VRd or KRd (carfilzomib, lenalidomide, and dexamethasone) in transplant-eligible multiple myeloma patients, while also considering administration logistics and supportive care requirements
STAT
OCTOBER 4, 2024
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Today’s item on bacterial outbreaks linked to hospital ice machines reminded me of The National’s song “Ice Machines,” so pardon me for slipping into music recommendation mode for a second.
Pharmacy Times
OCTOBER 4, 2024
Significant polarization surrounding COVID-19 vaccinations in late 2020 and early 2021 looked to have had an impact in increasing vaccine hesitancy.
STAT
OCTOBER 4, 2024
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
Pharmacy Times
OCTOBER 4, 2024
Carrie Koenigsfeld, PharmD, FAPhA, discusses an overview of RSV, including its transmission, incidence, seasonality, and clinical presentation.
Expert insights. Personalized for you.
132 
Let's personalize your content